Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth

Molecular Cell

Volumn 57, Issue 3, 2015, Pages 537-551

  Kashatus, Jennifer A ^a   Nascimento, Aldo ^a   Myers, Lindsey J ^a   Sher, Annie ^b   Byrne, Frances L ^c   Hoehn, Kyle L ^c   Counter, Christopher M ^b   Kashatus, David F ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE DRP1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; SERINE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIPHENYLAMINE; DNM1L PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL METABOLIC RATE; CANCER INHIBITION; CELL FUNCTION; CELL MEMBRANE POTENTIAL; CELL MOTION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEMBRANE STRUCTURE; MITOCHONDRIAL FISSION; MITOCHONDRION; MOUSE; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; MITOCHONDRIAL DYNAMICS; NUDE MOUSE; PANCREAS TUMOR; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; DIPHENYLAMINE; GENE KNOCKDOWN TECHNIQUES; GTP PHOSPHOHYDROLASES; HEK293 CELLS; HELA CELLS; HUMANS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RAS PROTEINS; SERINE;

EID: 84924761433     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.01.002     Document Type: Article

References (62)

1. Arismendi-Morillo G. Electron microscopy morphology of the mitochondrial network in human cancer. Int. J. Biochem. Cell Biol. 2009, 41:2062-2068.
2. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49:4682-4689.
3. Brunet A., Pagès G., Pouysségur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994, 9:3379-3387.
4. Bruns C.J., Harbison M.T., Kuniyasu H., Eue I., Fidler I.J. Invivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999, 1:50-62.
5. Carlson S.M., Chouinard C.R., Labadorf A., Lam C.J., Schmelzle K., Fraenkel E., White F.M. Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3. Sci. Signal. 2011, 4:rs11.
6. Chang C.-R., Blackstone C. Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J.Biol. Chem. 2007, 282:21583-21587.
7. Chen K.-H., Dasgupta A., Ding J., Indig F.E., Ghosh P., Longo D.L. Role of mitofusin 2 (Mfn2) in controlling cellular proliferation. FASEB J. 2014, 28:382-394.
8. Deer E.L., González-Hernández J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010, 39:425-435.
9. Diaz-Ruiz R., Uribe-Carvajal S., Devin A., Rigoulet M. Tumor cell energy metabolism and its common features with yeast metabolism. Biochim. Biophys. Acta 2009, 1796:252-265.
10. Diep C.H., Munoz R.M., Choudhary A., Von Hoff D.D., Han H. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin. Cancer Res. 2011, 17:2744-2756.
11. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
12. Ferreira L.M.R. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol. 2010, 89:372-380.
13. Gan X., Huang S., Wu L., Wang Y., Hu G., Li G., Zhang H., Yu H., Swerdlow R.H., Chen J.X., Yan S.S. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. Biochim. Biophys. Acta 2014, 1842:220-231.
14. Guo J.Y., Chen H.-Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., Kamphorst J.J., Chen G., Lemons J.M.S., Karantza V., et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011, 25:460-470.
15. Hagenbuchner J., Kuznetsov A.V., Obexer P., Ausserlechner M.J. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene 2013, 32:4748-4757.
16. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
17. Hamad N.M., Elconin J.H., Karnoub A.E., Bai W., Rich J.N., Abraham R.T., Der C.J., Counter C.M. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 2002, 16:2045-2057.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
19. Holcomb B., Yip-Schneider M.T., Matos J.M., Dixon J., Kennard J., Mahomed J., Shanmugam R., Sebolt-Leopold J., Schmidt C.M. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J.Gastrointest. Surg. 2008, 12:288-296.
20. Inoue-Yamauchi A., Oda H. Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells. Biochem. Biophys. Res. Commun. 2012, 421:81-85.
21. Karbowski M., Arnoult D., Chen H., Chan D.C., Smith C.L., Youle R.J. Quantitation of mitochondrial dynamics by photolabeling of individual organelles shows that mitochondrial fusion is blocked during the Bax activation phase of apoptosis. J.Cell Biol. 2004, 164:493-499.
22. Kashatus D.F., Lim K.-H., Brady D.C., Pershing N.L.K., Cox A.D., Counter C.M. RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat. Cell Biol. 2011, 13:1108-1115.
23. Kim J.-H., Kim H.Y., Lee Y.-K., Yoon Y.-S., Xu W.G., Yoon J.-K., Choi S.-E., Ko Y.-G., Kim M.-J., Lee S.-J., et al. Involvement of mitophagy in oncogenic K-Ras-induced transformation: overcoming a cellular energy deficit from glucose deficiency. Autophagy 2011, 7:1187-1198.
24. Levin-Salomon V., Kogan K., Ahn N.G., Livnah O., Engelberg D. Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinases. J.Biol. Chem. 2008, 283:34500-34510.
25. Liesa M., Shirihai O.S. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013, 17:491-506.
26. Lim K.-H., Baines A.T., Fiordalisi J.J., Shipitsin M., Feig L.A., Cox A.D., Der C.J., Counter C.M. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005, 7:533-545.
27. Lim K.-L., Ng X.-H., Grace L.G.-Y., Yao T.-P. Mitochondrial dynamics and Parkinson's disease: focus on parkin. Antioxid. Redox Signal. 2012, 16:935-949.
28. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
29. Lock R., Roy S., Kenific C.M., Su J.S., Salas E., Ronen S.M., Debnath J. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol. Biol. Cell 2011, 22:165-178.
30. Lozy F., Karantza V. Autophagy and cancer cell metabolism. Semin. Cell Dev. Biol. 2012, 23:395-401.
31. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
32. Mitra K. Mitochondrial fission-fusion as an emerging key regulator of cell proliferation and differentiation. Bioessays 2013, 35:955-964.
33. Mitra K., Wunder C., Roysam B., Lin G., Lippincott-Schwartz J. A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. Proc. Natl. Acad. Sci. USA 2009, 106:11960-11965.
34. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283:125-134.
35. Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T., Bassi C., Klöppel G., Kalthoff H., et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2001, 439:798-802.
36. Pitts K.R., McNiven M.A., Yoon Y. Mitochondria-specific function of the dynamin family protein DLP1 is mediated by its C-terminal domains. J.Biol. Chem. 2004, 279:50286-50294.
37. Qian W., Choi S., Gibson G.A., Watkins S.C., Bakkenist C.J., Van Houten B. Mitochondrial hyperfusion induced by loss of the fission protein Drp1 causes ATM-dependent G2/M arrest and aneuploidy through DNA replication stress. J.Cell Sci. 2012, 125:5745-5757.
38. Qian W., Wang J., Van Houten B. The role of dynamin-related protein 1 in cancer growth: a promising therapeutic target?. Expert Opin. Ther. Targets 2013, 17:997-1001.
39. Rao S., Tortola L., Perlot T., Wirnsberger G., Novatchkova M., Nitsch R., Sykacek P., Frank L., Schramek D., Komnenovic V., et al. A dualrole for autophagy in a murine model of lung cancer. Nat. Commun. 2014, 5:3056.
40. Rehman J., Zhang H.J., Toth P.T., Zhang Y., Marsboom G., Hong Z., Salgia R., Husain A.N., Wietholt C., Archer S.L. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 2012, 26:2175-2186.
41. Rosenfeldt M.T., Ryan K.M. The multiple roles of autophagy in cancer. Carcinogenesis 2011, 32:955-963.
42. Rosenfeldt M.T., O'Prey J., Morton J.P., Nixon C., MacKay G., Mrowinska A., Au A., Rai T.S., Zheng L., Ridgway R., et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013, 504:296-300.
43. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
44. Sheridan C., Martin S.J. Mitochondrial fission/fusion dynamics and apoptosis. Mitochondrion 2010, 10:640-648.
45. Shields J.M., Pruitt K., McFall A., Shaub A., Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 2000, 10:147-154.
46. Son J., Lyssiotis C.A., Ying H., Wang X., Hua S., Ligorio M., Perera R.M., Ferrone C.R., Mullarky E., Shyh-Chang N., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496:101-105.
47. Stanton V.P., Nichols D.W., Laudano A.P., Cooper G.M. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol. Cell. Biol. 1989, 9:639-647.
48. Stokes J.B., Adair S.J., Slack-Davis J.K., Walters D.M., Tilghman R.W., Hershey E.D., Lowrey B., Thomas K.S., Bouton A.H., Hwang R.F., et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 2011, 10:2135-2145.
49. Strohecker A.M., Guo J.Y., Karsli-Uzunbas G., Price S.M., Chen G.J., Mathew R., McMahon M., White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 2013, 3:1272-1285.
50. Su B., Wang X., Bonda D., Perry G., Smith M., Zhu X. Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease?. Mol. Neurobiol. 2010, 41:87-96.
51. Taguchi N., Ishihara N., Jofuku A., Oka T., Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J.Biol. Chem. 2007, 282:11521-11529.
52. Ushio-Fukai M., Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008, 266:37-52.
53. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
54. Wang C.-C., Bajikar S.S., Jamal L., Atkins K.A., Janes K.A. A time- and matrix-dependent TGFBR3-JUND-KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignancies. Nat. Cell Biol. 2014, 16:345-356.
55. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
56. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat. Rev. Mol. Cell Biol. 2010, 11:872-884.
57. Xia C., Meng Q., Liu L.-Z., Rojanasakul Y., Wang X.-R., Jiang B.-H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 2007, 67:10823-10830.
58. Yoon Y., Galloway C.A., Jhun B.S., Yu T. Mitochondrial dynamics in diabetes. Antioxid. Redox Signal. 2011, 14:439-457.
59. Youle R.J., Karbowski M. Mitochondrial fission in apoptosis. Nat. Rev. Mol. Cell Biol. 2005, 6:657-663.
60. Yu T., Jhun B.S., Yoon Y. High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid. Redox Signal. 2011, 14:425-437.
61. Zhang G.-E., Jin H.-L., Lin X.-K., Chen C., Liu X.-S., Zhang Q., Yu J.-R. Anti-tumor effects of mfn2 in gastric cancer. Int. J. Mol. Sci. 2013, 14:13005-13021.
62. Zhao J., Zhang J., Yu M., Xie Y., Huang Y., Wolff D.W., Abel P.W., Tu Y. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 2013, 32:4814-4824.